
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

Date of Report: May 19, 2015
Commission File Number: 001-36891

Collectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

<u>Exhibit</u>	<u>Title</u>
99.1	Press release, dated May 19, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLECTIS S.A.
(Registrant)

May 19, 2015

By: /s/ André Choulika

André Choulika
Chief Executive Officer

Collectis SA Combined General Shareholders' Meeting of May 18, 2015

PARIS--(BUSINESS WIRE)--May 19, 2015--Regulatory News:

The Combined General Shareholders' Meeting of Collectis S.A. (Paris:ALCLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS) was held on Monday, May 18, 2015 in Paris, at the Group's headquarters.

At the end of the meeting, during which more than 75% of votes were exercised, all of the ten resolutions submitted for the shareholders' vote were approved.

In particular, Collectis' shareholders voted on:

- the approval of the parent company and consolidated financial statements for the fiscal year ended December 31, 2014;
- term of office renewal of directors Mr André Choulika, Mr David Sourdivé and Mr Alain Godard;
- the approval of regulated agreements;
- the authorization of a share repurchase plan and the authorization given to the Board of Directors to retire the shares acquired through it;
- the nomination of a new Director, Mr Jean-Marie Messier.

Jean-Marie Messier, 58 years old, is co-founder and head of Messier Maris & Associés, an investment bank headquartered in Paris and New-York. Messier Maris & Associés is recognized as a leading independent corporate finance advisor in mergers and acquisitions, financial restructuring and equity / debt advisory.

The full results of the vote can be examined on the company's website (www.collectis.com).

About Collectis

Collectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.collectis.com

CONTACT:**Media contact**

Jennifer Moore, Director of Communications

Phone: 917-580-1088

email: media@collectis.com

or

BMC Communications

Brad Miles

Phone: 646-513-3125

email: bmiles@bmccommunications.com

or

IR contact

Simon Harnest, VP Finance and Investor Relations

Phone: 646-385-9008

email: simon.harnest@collectis.com